U.S. Building Stock News

General Mills (GIS) finds itself in the spotlight after a string of headwinds, including flat sales in its North America retail division, fallout from rising costs, and conservative expectations for the upcoming year. Investors are watching how the company will respond amid ongoing industry changes and tighter competition. See our latest analysis for General Mills. The past year has been rough for General Mills shareholders, with the stock’s total return falling over 21%. Despite recent...

Invitation Homes (INVH) held its Analyst and Investor Day at a time when several analysts pulled back on their outlook, keeping ratings steady but lowering expectations. The event provided updates on strategy and operations, but persistent housing market headwinds still cloud the near-term view. See our latest analysis for Invitation Homes. Invitation Homes' latest share price sits at $28.39. While the stock has shown a bumpy ride this year, pressure from the broader housing market has...

monday.com released its third quarter 2025 results, reporting sales of US$316.86 million and turning a net profit of US$13.05 million, compared to a net loss a year earlier. While revenue growth and profitability were strong, the company's guidance for fourth quarter revenue came in below analyst forecasts, raising concerns about market conditions and future momentum. We'll consider how monday.com's cautious fourth quarter revenue outlook shapes its investment narrative and future growth...

UBiqube has expanded its SASE OpsLabs enablement portal to integrate with Netskope (NTSK), rolling out automation kits designed to simplify secure network deployments and migrations for large enterprises. This integration is intended to streamline adoption and reduce manual workloads. See our latest analysis for Netskope. After last week’s announcement of UBiqube’s integration, there has been heightened attention on Netskope, though its shares have not reversed the negative momentum...

On November 5, 2025, RenaissanceRe Holdings announced a share repurchase program authorizing up to US$750 million in buybacks, alongside affirming its quarterly dividend of US$0.40 per share to be paid on December 31, 2025. This combination of direct capital return through buybacks and sustained dividend payments often signals management confidence in operational performance and a focus on shareholder value. Now, we'll explore how the sizeable buyback authorization could influence...

Royalty Pharma reported third quarter 2025 revenue of US$609.29 million, an increase from a year earlier, and raised its full-year Portfolio Receipts guidance to a range of US$3.20 billion to US$3.25 billion. This guidance revision comes alongside an ongoing share repurchase program and follows a period where the company's long-term growth and profitability have been questioned by the market. We’ll examine how Royalty Pharma’s upgraded 2025 revenue guidance could influence its investment...

BeOne Medicines (NasdaqGS:ONC) stock reacted to the company’s third-quarter results, which featured a major swing into profitability and better than expected revenue growth. Management also raised annual guidance, signaling optimism for continued momentum. See our latest analysis for BeOne Medicines. After a year of strong momentum, BeOne Medicines’ latest 15.6% one-month share price return and 98.8% year-to-date gain signal a market rally driven by upbeat earnings, raised guidance, and...

Everest Group (EG) shares have been under pressure recently, with returns tracking lower over the past month. Investors are starting to take a closer look at what is driving performance and how fundamentals might shape expectations in the coming quarters. See our latest analysis for Everest Group. Everest Group has faced some headwinds, with its latest share price settling at $326.23 and a 1-year total shareholder return of -10.6%. While the stock has given back some ground this year, its...

Immunocore Holdings recently announced positive Phase 1 trial results for its IMC-I109V candidate in hepatitis B, alongside reporting higher third-quarter and nine-month revenues with narrowing net losses as of September 30, 2025. Early data showed IMC-I109V was generally well tolerated and produced reductions in hepatitis B surface antigen, an important marker for infection, supporting further development of this new immunotherapy. We'll explore how promising Phase 1 trial evidence for...

DraftKings recently reported third quarter 2025 results showing sales of US$1.14 billion and a net loss of US$256.79 million, missing analyst expectations and leading management to lower full-year revenue guidance to between US$5.9 billion and US$6.1 billion. At the same time, DraftKings expanded its share repurchase authorization by US$1.0 billion to a total of US$2.0 billion and saw board members buy shares after the earnings report, signaling confidence even as cost pressures and...

Turning Point Brands (TPB) caught attention after posting third-quarter results that showed solid growth in both sales and net income compared to last year. Investors also took note because the company raised its full-year outlook for its Modern Oral segment, signaling ongoing confidence in future performance. See our latest analysis for Turning Point Brands. Momentum has been building for Turning Point Brands all year, with the stock’s 1-year total shareholder return hitting 67.4% and its...

Synovus Financial Corp. recently reported third-quarter 2025 adjusted earnings per share of US$1.46, exceeding estimates due to higher net interest income, stronger non-interest revenues, and reduced provisions for credit losses. Management also highlighted significant improvements in credit quality, with declines in non-performing loans and charge-offs as well as expectations for continued growth in core deposits and loans in the coming quarters. We'll explore how Synovus's earnings...

RLJ Lodging Trust recently reported third quarter 2025 earnings, disclosing a decline in revenue to US$330.05 million and a net loss of US$3.74 million, while also providing updated guidance with full-year net income expected between US$21.4 million and US$28.4 million. The company’s ongoing share repurchase program has seen 586,417 shares bought back since May, reflecting management’s continued use of capital return initiatives even during weaker financial quarters. We’ll look at how RLJ...

Shift4 Payments (FOUR) recently posted third-quarter results, with revenue up compared to last year but net income declining. In response, several analysts lowered their expectations while keeping mostly neutral or positive outlooks. See our latest analysis for Shift4 Payments. Shift4 Payments has seen some turbulence in its stock price lately, reflecting both the mixed signals from recent earnings and a major new deal with the Cincinnati Bengals to power Paycor Stadium’s payments. While the...

Dover (DOV) has just wrapped up a significant euro-denominated bond issuance, adding nearly €550 million in fresh capital. The company also moved forward with another fixed-rate senior note offering. This underscores a proactive approach to managing its finances. See our latest analysis for Dover. Building on this week’s successful bond issuance and a recently reaffirmed dividend, Dover’s share price has charged ahead, with a robust 10% gain over the past month. Still, its one-year total...

Royal Gold, Inc. recently reported third quarter and nine-month earnings, announcing US$249.65 million in sales and US$126.82 million in net income for the quarter, both higher than the previous year. This strong operational performance was accompanied by routine shelf registration filings for both an employee stock plan and a dividend reinvestment plan. We'll explore how Royal Gold's significant year-over-year earnings growth impacts its investment narrative and future prospects. This...

Protagonist Therapeutics (PTGX) posted its third-quarter earnings, showing a shift to a higher net loss compared to last year. The company also moved from net income to net loss for the nine months ended September 30. See our latest analysis for Protagonist Therapeutics. Despite shifting to a deeper net loss in the latest earnings, Protagonist Therapeutics' share price has surged 117% year to date, with a strong one year total shareholder return of 109%. This impressive momentum hints at...

Fidium’s decision to roll out Ciena (CIEN) optical technology across its DASH fiber network in Texas puts a fresh spotlight on Ciena’s growing role in next-generation telecom infrastructure. The deployment signals steady demand for scalable and high-capacity solutions. See our latest analysis for Ciena. Ciena’s recent win with Fidium adds to the company’s momentum this year, as the stock has delivered a remarkable 130% share price gain year-to-date and an even more impressive 188% total...

On November 5, 2025, ADMA Biologics reported third quarter results with sales of US$134.22 million and net income of US$36.43 million, alongside raising its 2025 and 2026 revenue guidance and providing a long-term outlook for US$1.1 billion or more in annual revenue by 2029. The company's ongoing share repurchase program, coupled with an improved earnings forecast, highlights management's confidence in operational progress and future growth prospects. With the company raising revenue...

Coty (COTY) recently delivered an earnings report that matched revenue expectations, but revealed softer profit performance. The company pointed to challenges from the Gucci fragrance license transition and inventory adjustments at key retailers. See our latest analysis for Coty. Even with Coty’s latest reassurance about future growth, the market remains unconvinced for now. The stock’s 1-day share price return was -3.58%, capping off a punishing 90-day slide of -28.43%. Over the past year,...

Air Products and Chemicals, Inc. recently reported fourth quarter 2025 earnings, with sales of US$3,166.9 million and net income of US$4.9 million, both down from the same period last year, alongside basic and diluted earnings per share of US$0.02. A significant drop in earnings was attributed to lower volumes, a one-time LNG asset sale, and weaker global helium demand, partially offset by reduced administrative expenses reflecting ongoing productivity efforts. We will now assess how this...

Brinker International (EAT) delivered impressive quarterly results, with Chili's showing sales and traffic growth even as broader economic trends remained challenging. The company’s positive momentum has encouraged investors and supported a more upbeat outlook. See our latest analysis for Brinker International. Brinker International’s upbeat quarterly numbers sparked a 6.1% leap in the share price last month, briefly reversing what has otherwise been a tough stretch for the stock. While its...

Primerica posted its third quarter earnings, revealing higher revenue and net income compared to the same period last year. Alongside these financial gains, the company affirmed its dividend and completed another share buyback tranche. See our latest analysis for Primerica. After announcing stronger earnings, a fresh dividend, and more buybacks, Primerica's share price dipped slightly in recent weeks, landing at $254.05. Despite this, the total shareholder return stands out long-term, with...

Fidelity National Financial (FNF) shares have mostly tracked sideways over the past month, up about 5%. Despite market swings, investors are still weighing the company’s revenue and earnings performance in light of ongoing trends in the insurance sector. See our latest analysis for Fidelity National Financial. Fidelity National Financial’s share price return has edged higher by 4% since the start of the year, yet the total shareholder return over the last twelve months is slightly negative at...